Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Abstract ROS1 is the largest receptor tyrosine kinase in the human genome. Rearrangements of the ROS1 gene result in oncogenic ROS1 kinase fusion proteins that are currently the only validated biomarkers for targeted therapy with ROS1 TKIs in patients. While numerous somatic missense mutations in RO...

Full description

Bibliographic Details
Main Authors: Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare
Format: Article
Language:English
Published: Springer Nature 2023-10-01
Series:EMBO Molecular Medicine
Subjects:
cancer mutations
ROS1
TKI
Online Access:https://doi.org/10.15252/emmm.202217367

Internet

https://doi.org/10.15252/emmm.202217367

Similar Items